Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor

Journal of Molecular Biology

Volumn 331, Issue 4, 2003, Pages 815-828

  Watkins, Ryan E ^a   Davis Searles, Paula R ^a,c   Lambert, Mill H ^b   Redinbo, Matthew R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Coactivator; Nuclear receptor; PXR; SRC 1; Xenobiotic

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; PREGNANE X RECEPTOR; SR 12813; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; SURFACE PROPERTY; THERMODYNAMICS; THERMOSTABILITY;

EID: 0043168030     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00795-2     Document Type: Article

References (84)

1. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1998;1016-1023.
2. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:2001;14581-14587.
3. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug. Metab. Dispos. 29:2001;242-251.
4. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277:2002;209-217.
5. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 7:2001;584-590.
6. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 92:1998;73-82.
7. Rosenfeld J.M., Vargas R. Jr, Xie W., Evans R.M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor PXR. Mol. Endocrinol. 17:2003;1268-1282.
8. Takeshita A., Koibuchi N., Oka J., Taguchi M., Shishiba Y., Ozawa Y. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur. J. Endocrinol. 145:2001;513-517.
9. Masuyama H., Hiramatsu Y., Kunitomi M., Kudo T., MacDonald P.N. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate pregnane X receptor-mediated transcription. Mol. Endocrinol. 14:2000;421-428.
10. Handschin C., Podvinec M., Stockli J., Hoffmann K., Meyer U.A. Conservation of signaling pathways of xenobiotic-sensing orphan nuclear receptors, chicken xenobiotic receptor, constitutive androstane receptor, and pregnane X receptor, from birds to humans. Mol. Endocrinol. 15:2001;1571-1585.
11. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J., Buckley A.R. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug. Metab. Dispos. 30:2002;608-612.
12. Dussault I., Lin M., Hollister K., Wang E.H., Synold T.W., Forman B.M. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276:2001;33309-33312.
13. Drocourt L., Pascussi J.M., Assenat E., Fabre J.M., Maurel P., Vilarem M.J. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of cyp3a, cyp2b, and cyp2c in human hepatocytes. Drug. Metab. Dispos. 29:2001;1325-1331.
14. Wright M.C. The cytochrome P450 3A4 inducer metyrapone is an activator of the human pregnane X receptor. Biochem. Soc. Trans. 27:1999;387-391.
15. Schuetz E.G., Brimer C., Schuetz J.D. Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol. Pharmacol. 54:1998;1113-1117.
16. Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56:1999;1329-1339.
17. Jones S.A., Moore L.B., Shenk J.L., Wisely G.B., Hamilton G.A., McKee D.D., et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:2000;27-39.
18. Landes N., Pfluger P., Kluth D., Birringer M., Ruhl R., Bol G.F., et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem. Pharmacol. 65:2003;269-273.
19. Coumoul X., Diry M., Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol. 64:2002;1513-1519.
20. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., Kliewer S.A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 62:2002;638-646.
21. Moore L.B., Parks D.J., Jones S.A., Bledsoe R.K., Consler T.G., Stimmel J.B., et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:2000;15122-15127.
22. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369:1999;11-23.
23. Xie W., Barwick J.L., Simon C.M., Pierce A.M., Safe S., Blumberg B., et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14:2000;3014-3023.
24. Mathijssen R.H., Verweij J., de Bruijn P., Loos W.J., Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J. Natl Cancer Inst. 94:2002;1247-1249.
25. Ernst E. Second thoughts about safety of St John's wort. Lancet. 354:1999;2014-2016.
26. Ernst E., Rand J.I., Barnes J., Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 54:1998;589-594.
27. Fugh-Berman A. Herb-drug interactions. Lancet. 355:2000;134-138.
28. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falloon J. Indinavir concentrations and St John's wort. Lancet. 355:2000;547-548.
29. Ruschitzka F., Meier P.J., Turina M., Luscher T.F., Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 355:2000;548-549.
30. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA. 97:2000;7500-7502.
31. Wentworth J.M., Agostini M., Love J., Schwabe J.W., Chatterjee V.K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol. 166:2000;R11-R16.
32. Blumberg B., Sabbagh W. Jr, Juguilon H., Bolado J. Jr, van Meter C.M., Ong E.S., Evans R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:1998;3195-3205.
33. Bertilsson G., Berkenstam A., Blomquist P. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 280:2001;139-144.
34. Xie W., Barwick J.L., Downes M., Blumberg B., Simon C.M., Nelson M.C., et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 406:2000;435-439.
35. Watkins R.E., Maglich J.M., Moore L.B., Wisely G.B., Noble S.M., Davis-Searles P.R., et al. 2.1 Å crystal structure of human PXR in complex with the St. John's Wort compound hyperforin. Biochemistry. 42:2003;1430-1438.
36. Savas U., Griffin K.J., Johnson E.F. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: an expanded role for nuclear hormone receptors. Mol. Pharmacol. 56:1999;851-857.
37. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292:2001;2329-2333.
38. Watkins R.E., Noble S.M., Redinbo M.R. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Dev. 5:2002;150-158.
39. Yao T.P., Ku G., Zhou N., Scully R., Livingston D.M. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl Acad. Sci. USA. 93:1996;10626-10631.
40. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
41. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
42. Chen D., Ma H., Hong H., Koh S.S., Huang S.M., Schurter B.T., et al. Regulation of transcription by a protein methyltransferase. Science. 284:1999;2174-2177.
43. Schurter B.T., Koh S.S., Chen D., Bunick G.J., Harp J.M., Hanson B.L., et al. Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry. 40:2001;5747-5756.
44. Xu W., Chen H., Du K., Asahara H., Tini M., Emerson B.M., et al. A transcriptional switch mediated by cofactor methylation. Science. 294:2001;2507-2511.
45. Gampe R.T. Jr, Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5:2000;545-555.
46. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143.
47. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA. 98:2001;13919-13924.
48. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519.
49. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 387:1997;733-736.
50. Kallenberger B.C., Love J.D., Chatterjee V.K., Schwabe J.W. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nature Struct. Biol. 10:2003;136-140.
51. Egea P.F., Mitschler A., Moras D. Molecular recognition of agonist ligands by RXRs. Mol. Endocrinol. 16:2002;987-997.
52. Greschik H., Wurtz J.M., Sanglier S., Bourguet W., van Dorsselaer A., Moras D., Renaud J.P. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol. Cell. 9:2002;303-313.
53. Darimont B.D., Wagner R.L., Apriletti J.W., Stallcup M.R., Kushner P.J., Baxter J.D., et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12:1998;3343-3356.
54. Stehlin C., Wurtz J.M., Steinmetz A., Greiner E., Schule R., Moras D., Renaud J.P. X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. EMBO J. 20:2001;5822-5831.
55. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature Struct. Biol. 9:2002;359-364.
56. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
57. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 415:2002;813-817.
58. LoConte L., Chothia C., Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:1999;2177-2198.
59. Cronet P., Petersen J.F., Folmer R., Blomberg N., Sjoblom K., Karlsson U., et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure (Camb). 9:2001;699-706.
60. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature. 393:1998;392-396.
61. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 375:1995;377-382.
62. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Moras D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
63. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
64. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275:2000;26164-26171.
65. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell. 5:2000;173-179.
66. Wagner R.L., Apriletti J.W., McGrath M.E., West B.L., Baxter J.D., Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature. 378:1995;690-697.
67. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell. 3:1999;397-403.
68. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 5:2000;289-298.
69. Love J.D., Gooch J.T., Benko S., Li C., Nagy L., Chatterjee V.K., et al. The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. J. Biol. Chem. 277:2002;11385-11391.
70. Heery D.M., Hoare S., Hussain S., Parker M.G., Sheppard H. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 276:2001;6695-6702.
71. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141.
72. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110:2002;93-105.
73. Coulthard V.H., Matsuda S., Heery D.M. An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J. Biol. Chem. 278:2003;10942-10951.
74. Greenfield N., Vijayanathan V., Thomas T.J., Gallo M.A., Thomas T. Increase in the stability and helical content of estrogen receptor alpha in the presence of the estrogen response element: analysis by circular dichroism spectroscopy. Biochemistry. 40:2001;6646-6652.
75. Pissios P., Tzameli I., Kushner P., Moore D.D. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol. Cell. 6:2000;245-253.
76. Johnson B.A., Wilson E.M., Li Y., Moller D.E., Smith R.G., Zhou G. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J. Mol. Biol. 298:2000;187-194.
77. Otwinowski, Z. & Minor, W. (1997). Data Collection and Processing, Warrington, UK.
78. Navaza J., Saludjian P. AMoRe: an automated molecular replacement package. Methods Enzymol. 276:1997;581-594.
79. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
80. Brünger A.T. Assessment of phase accuracy by cross validation: the free R-value. Methods and applications. Acta Crystallog. sect. D. 49:1993;24-36.
81. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
82. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
83. Nicholls A., Sharp K., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Funct. Genet. 11:1991;281-296.
84. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.